4th Nov 2021 12:35
Belluscura PLC - London-based medical device developer - Says demand for X-PLO2R portable oxygen concentrator has significantly exceeded initial expectations. Firm has now beat anticipated sales volume for 2021 and expects run rate for unit sales and revenue in 2022 to be materially ahead of current market forecasts. "Based upon the current growth prospects and opportunities, the company has entered into an updated partnership agreement with its US based manufacturing partner to increase production capacity to meet anticipated demand for financial 22 and beyond," the oxygen enrichment technology developer says.
Current stock price: 100.48 pence, up 2.0%
Change since listing at end of May: up 90%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Belluscura